Stonebridge Financial Group LLC Makes New $195,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Stonebridge Financial Group LLC purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 2,640 shares of the medical research company’s stock, valued at approximately $195,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Focus Financial Network Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $206,000. Equitable Trust Co. increased its holdings in shares of Edwards Lifesciences by 10.9% in the 4th quarter. Equitable Trust Co. now owns 73,042 shares of the medical research company’s stock worth $5,407,000 after buying an additional 7,154 shares during the last quarter. Ferguson Wellman Capital Management Inc. raised its position in shares of Edwards Lifesciences by 2.7% during the 4th quarter. Ferguson Wellman Capital Management Inc. now owns 27,692 shares of the medical research company’s stock valued at $2,050,000 after buying an additional 718 shares in the last quarter. Birch Hill Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 90.3% during the 4th quarter. Birch Hill Investment Advisors LLC now owns 738,779 shares of the medical research company’s stock worth $54,692,000 after acquiring an additional 350,650 shares during the last quarter. Finally, Empowered Funds LLC grew its position in Edwards Lifesciences by 6.2% in the fourth quarter. Empowered Funds LLC now owns 25,533 shares of the medical research company’s stock worth $1,890,000 after acquiring an additional 1,501 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.2 %

NYSE EW opened at $70.95 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a market cap of $41.85 billion, a P/E ratio of 10.24, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The stock has a 50 day simple moving average of $72.46 and a two-hundred day simple moving average of $69.26.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. The Goldman Sachs Group lifted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Royal Bank of Canada raised their price objective on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Barclays upped their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Truist Financial reissued a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $79.19.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.